American Journal of Kidney Diseases
Volume 54, Issue 4 , Pages 665-673 , October 2009

Association of Kidney Function With Residual Hypertension After Treatment of Aldosterone-Producing Adenoma

  • Vin-Cent Wu, MD

      Affiliations

    • Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan
    • ,
  • Shih-Chieh Chueh, MD, PhD

      Affiliations

    • Department of Urology, National Taiwan University Hospital, Taipei, Taiwan
    • Cleveland Clinic Glickman Urological and Kidney Institute, Cleveland, OH
    • ,
  • Hung-Wei Chang, MD, PhD

      Affiliations

    • Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan
    • ,
  • Lian-Yu Lin, MD, PhD

      Affiliations

    • Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan
    • ,
  • Kao-Lang Liu, MD

      Affiliations

    • Department of Medical Image, National Taiwan University Hospital, Taipei, Taiwan
    • ,
  • Yen-Hung Lin, MD

      Affiliations

    • Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan
    • ,
  • Yi-Luwn Ho, MD, PhD

      Affiliations

    • Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan
    • ,
  • Wei-Chou Lin, MD

      Affiliations

    • Department of Pathology, National Taiwan University Hospital, Taipei, Taiwan
    • ,
  • Shuo-Meng Wang, MD

      Affiliations

    • Department of Medical Image, National Taiwan University Hospital, Taipei, Taiwan
    • ,
  • Kuo-How Huang, MD

      Affiliations

    • Department of Medical Image, National Taiwan University Hospital, Taipei, Taiwan
    • ,
  • Kuan-Yu Hung, MD, PhD

      Affiliations

    • Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan
    • ,
  • Tze-Wah Kao, MD

      Affiliations

    • Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan
    • ,
  • Shuei-Liong Lin, MD, PhD

      Affiliations

    • Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan
    • ,
  • Ruoh-Fang Yen, MD, PhD

      Affiliations

    • Department of Nuclear Medicine, National Taiwan University Hospital, Taipei, Taiwan
    • ,
  • Yung-Ming Chen, MD

      Affiliations

    • Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan
    • ,
  • Bor-Sen Hsieh, MD, PhD

      Affiliations

    • Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan
    • ,
  • Kwan-Dun Wu, MD, PhD

      Affiliations

    • Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan
    • Corresponding Author InformationAddress correspondence to Kwan-Dun Wu, MD, PhD, Rm 1419, Clinical Research Bldg, Department of Internal Medicine, National Taiwan University Hospital, 7 Chung-Shan South Rd, Taipei 100, Taiwan
    • ,
  • TAIPAI Study Group

Received 3 December 2008 ,Accepted 2 June 2009.

References 

  1. Wu KD, Liao TS, Chen YM, et al. Presurgery diagnosis and localization of aldosterone-producing adenoma by adrenal venous sampling after administration of metoclopramide. J Formos Med Assoc. 2001;100:598–603
  2. Rossi GP, Bernini G, Caliumi C, et al. A prospective study of the prevalence of primary aldosteronism in 1,125 hypertensive patients. J Am Coll Cardiol. 2006;48:2293–2300
  3. Nomura K, Toraya S, Horiba N, et al. Plasma aldosterone response to upright posture and angiotensin II infusion in aldosterone-producing adenoma. J Clin Endocrinol Metab. 1992;75:323–327
  4. Blumenfeld JD, Sealey JE, Schlussel Y, et al. Diagnosis and treatment of primary hyperaldosteronism. Ann Intern Med. 1994;121:877–885
  5. Lim PO, Jung RT, MacDonald TM. Raised aldosterone to renin ratio predicts antihypertensive efficacy of spironolactone: A prospective cohort follow-up study. Br J Clin Pharmacol. 1999;48:756–760
  6. Lumachi F, Ermani M, Basso SM, et al. Long-term results of adrenalectomy in patients with aldosterone-producing adenomas: Multivariate analysis of factors affecting unresolved hypertension and review of the literature. Am Surg. 2005;71:864–869
  7. Sawka AM, Young WF, Thompson GB, et al. Primary aldosteronism: Factors associated with normalization of blood pressure after surgery. Ann Intern Med. 2001;135:258–261
  8. Proye CA, Mulliez EA, Carnaille BM, et al. Essential hypertension: First reason for persistent hypertension after unilateral adrenalectomy for primary aldosteronism?. Surgery. 1998;124:1128–1133
  9. Milliez P, Girerd X, Plouin PF, et al. Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. J Am Coll Cardiol. 2005;45:1243–1248
  10. Rossi GP, Belfiore A, Bernini G, et al. Prospective evaluation of the saline infusion test for excluding primary aldosteronism due to aldosterone-producing adenoma. J Hypertens. 2007;25:1433–1442
  11. Schillaci G, Reboldi G, Verdecchia P. High-normal serum creatinine concentration is a predictor of cardiovascular risk in essential hypertension. Arch Intern Med. 2001;161:886–891
  12. Wang TJ, Evans JC, Meigs JB, et al. Low-grade albuminuria and the risks of hypertension and blood pressure progression. Circulation. 2005;111:1370–1376
  13. Leoncini G, Viazzi F, Parodi D, et al. Creatinine clearance and signs of end-organ damage in primary hypertension. J Hum Hypertens. 2004;18:511–516
  14. Rossi GP, Bolognesi M, Rizzoni D, et al. Vascular remodeling and duration of hypertension predict outcome of adrenalectomy in primary aldosteronism patients. Hypertension. 2008;51:1366–1371
  15. Ribstein J, Du Cailar G, Fesler P, Mimran A. Relative glomerular hyperfiltration in primary aldosteronism. J Am Soc Nephrol. 2005;16:1320–1325
  16. Sechi LA, Novello M, Lapenna R, et al. Long-term renal outcomes in patients with primary aldosteronism. JAMA. 2006;295:2638–2645
  17. Horita Y, Inenaga T, Nakahama H, et al. Cause of residual hypertension after adrenalectomy in patients with primary aldosteronism. Am J Kidney Dis. 2001;37:884–889
  18. Arima S, Kohagura K, Xu HL, et al. Endothelium-derived nitric oxide modulates vascular action of aldosterone in renal arteriole. Hypertension. 2004;43:352–357
  19. Rossi GP, Bernini G, Desideri G, et al. Renal damage in primary aldosteronism: Results of the PAPY Study. Hypertension. 2006;48:232–238
  20. Wu VC, Chang HW, Liu KL, et al. Primary aldosteronism: Diagnostic accuracy of the losartan and captopril tests. [e-pub ahead of print]. Am J Hypertens doi: 10.1038/ajh.2009.89accessed July 15, 2009
  21. Wu VC, Chueh SC, Chang HW, et al. Bilateral aldosterone-producing adenomas: Differentiation from bilateral adrenal hyperplasia. QJM. 2008;101:13–22
  22. Chen YM, Hsieh BS, Wu KD, Chu TS. Exaggerated natriuresis in primary aldosteronism. J Formos Med Assoc. 1991;90:927–931
  23. Funder JW, Carey RM, Fardella C, et al. Case detection, diagnosis, and treatment of patients with primary aldosteronism: An endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2008;93:3266–3281
  24. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation. J Chronic Dis. 1987;40:373–383
  25. Levey AS, Bosch JP, Lewis JB, et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation (Modification of Diet in Renal Disease Study Group). Ann Intern Med. 1999;130:461–470
  26. Levey AS, Coresh J, Balk E, et al. National Kidney Foundation practice guidelines for chronic kidney disease: Evaluation, classification, and stratification. Ann Intern Med. 2003;139:137–147
  27. Chang HW, Chu TS, Huang HY, et al. Down-regulation of D2 dopamine receptor and increased protein kinase Cmu phosphorylation in aldosterone-producing adenoma play roles in aldosterone overproduction. J Clin Endocrinol Metab. 2007;92:1863–1870
  28. Molloy TJ, Okin PM, Devereux RB, Kligfield P. Electrocardiographic detection of left ventricular hypertrophy by the simple QRS voltage-duration product. J Am Coll Cardiol. 1992;20:1180–1186
  29. Sokolow M, Lyon TP. The ventricular complex in left ventricular hypertrophy as obtained by unipolar precordial and limb leads. Am Heart J. 1949;37:161–182
  30. Liao CH, Chueh SC, Lai MK, et al. Laparoscopic adrenalectomy for potentially malignant adrenal tumors greater than 5 centimeters. J Clin Endocrinol Metab. 2006;91:3080–3083
  31. Rundback JH, Sacks D, Kent KC, et al. Guidelines for the reporting of renal artery revascularization in clinical trials (American Heart Association). Circulation. 2002;106:1572–1585
  32. Catena C, Colussi G, Lapenna R, et al. Long-term cardiac effects of adrenalectomy or mineralocorticoid antagonists in patients with primary aldosteronism. Hypertension. 2007;50:911–918
  33. Hanley JA, McNeil BJ. The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology. 1982;143:29–36
  34. Lemeshow S, Hosmer DW. A review of goodness of fit statistics for use in the development of logistic regression models. Am J Epidemiol. 1982;115:92–106
  35. Woo MJ, Reiter JP, Karr AF. Estimation of propensity scores using generalized additive models. Stat Med. 2008;27:3805–3816
  36. Rossi GP, Sacchetto A, Visentin P, et al. Changes in left ventricular anatomy and function in hypertension and primary aldosteronism. Hypertension. 1996;27:1039–1045
  37. Pierce GL, Beske SD, Lawson BR, et al. Weight loss alone improves conduit and resistance artery endothelial function in young and older overweight/obese adults. Hypertension. 2008;52:72–79
  38. Pitt B, Remme W, Zannad F, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003;348:1309–1321
  39. Rizzoni D, Porteri E, Castellano M, et al. Vascular hypertrophy and remodeling in secondary hypertension. Hypertension. 1996;28:785–790
  40. Farquharson CA, Struthers AD. Spironolactone increases nitric oxide bioactivity, improves endothelial vasodilator dysfunction, and suppresses vascular angiotensin I/angiotensin II conversion in patients with chronic heart failure. Circulation. 2000;101:594–597
  41. Giacchetti G, Ronconi V, Turchi F, et al. Aldosterone as a key mediator of the cardiometabolic syndrome in primary aldosteronism: An observational study. J Hypertens. 2007;25:177–186
  42. Obara T, Ito Y, Okamoto T, et al. Risk factors associated with postsurgery persistent hypertension in patients with primary aldosteronism. Surgery. 1992;112:987–993
  43. Fukudome Y, Fujii K, Arima H, et al. Discriminating factors for recurrent hypertension in patients with primary aldosteronism after adrenalectomy. Hypertens Res. 2002;25:11–18
  44. Catena C, Colussi G, Nadalini E, et al. Relationships of plasma renin levels with renal function in patients with primary aldosteronism. Clin J Am Soc Nephrol. 2007;2:722–731
  45. Catena C, Colussi G, Sechi LA. Renal function in primary aldosteronism. author reply, e111 Hypertension. 2006;48:e110;(letter)
  46. Hall JE, Granger JP, Smith MJ, Premen AJ. Role of renal hemodynamics and arterial pressure in aldosterone “escape.”. Hypertension. 1984;6:I183–I192
  47. Zuo L, Ma YC, Zhou YH, et al. Application of GFR-estimating equations in Chinese patients with chronic kidney disease. Am J Kidney Dis. 2005;45:463–472

 Originally published online as doi: 10.1053/j.ajkd.2009.06.014 on July 24, 2009.

 A list of the members of the TAIPAI Study Group appears at the end of this article.

PII: S0272-6386(09)00877-4

doi: 10.1053/j.ajkd.2009.06.014

American Journal of Kidney Diseases
Volume 54, Issue 4 , Pages 665-673 , October 2009

Article Tools

* Image Usage & Resolution